key: cord-0777529-par7lp1z authors: Hernández Cordero, Ana I.; Li, Xuan; Yang, Chen Xi; Milne, Stephen; Bossé, Yohan; Joubert, Philippe; Timens, Wim; van den Berge, Maarten; Nickle, David; Hao, Ke; Sin, Don D. title: Gene Expression Network Analysis Provides Potential Targets Against SARS-CoV-2 date: 2020-07-06 journal: bioRxiv DOI: 10.1101/2020.07.06.182634 sha: 3acbf9fcbddcc119d8788e69f5df3604697e3df2 doc_id: 777529 cord_uid: par7lp1z BACKGROUND Cell entry of SARS-CoV-2, the novel coronavirus causing COVID-19, is facilitated by host cell angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). We aimed to identify and characterize genes that are co-expressed with ACE2 and TMPRSS2, and to further explore their biological functions and potential as druggable targets. METHODS Using the gene expression profiles of 1,038 lung tissue samples, we performed a weighted gene correlation network analysis (WGCNA) to identify modules of co-expressed genes. We explored the biology of co-expressed genes using bioinformatics databases, and identified known drug-gene interactions. RESULTS ACE2 was in a module of 681 co-expressed genes; 12 genes with moderate-high correlation with ACE2 (r>0.3, FDR<0.05) had known interactions with existing drug compounds. TMPRSS2 was in a module of 1,086 co-expressed genes; 15 of these genes were enriched in the gene ontology biologic process ‘Entry into host cell’, and 53 TMPRSS2-correlated genes had known interactions with drug compounds. CONCLUSION Dozens of genes are co-expressed with ACE2 and TMPRSS2, many of which have plausible links to COVID-19 pathophysiology. Many of the co-expressed genes are potentially targetable with existing drugs, which may help to fast-track the development of COVID-19 therapeutics. associates with the angiotensin-converting enzyme 2 (ACE2) to mediate infection of the target cells9. 79 ACE2 is a type 1 transmembrane metallocarboxypeptidase that is an important negative regulator of 80 the renin-angiotensin system (RAS). Once SARS-CoV-2 gains entry into epithelial cells, surface 81 expression of ACE2 is rapidly downregulated in the infected cell 10, which leads to an imbalance in 82 angiotensin II-mediated signalling and predisposes the host to acute lung injury. SARS-CoV-2 also 83 employs transmembrane serine protease 2 (TMPRSS2) to proteolytically activate the S protein, which 84 is essential for viral entry into target cells 11. 85 86 In view of the rapid spread and the mortality of COVID-19 worldwide, there is an urgent need 87 to find effective treatments against this infection, especially for severe cases. However, the 88 development of a vaccine and novel treatments may take months to years, requiring billions of dollars 89 in investment and with no certainty of their ultimate success. Bioinformatic approaches, however, can 90 rapidly identify relevant gene-drug interactions that may contribute to the understanding of the 91 mechanisms of viral infection and reduce the time to finding potential drug targets and existing drugs 92 that could be repurposed for this indication. Here, we performed a gene expression network analysis 93 on data generated in the Lung eQTL Consortium Cohort to investigate the mechanisms of ACE2 and 94 TMPRSS2 expression in lung tissue. We identified potential targets to be explored as possible 95 treatments for COVID-19. We hypothesized that the mechanisms associated with ACE2 and TMPRSS2 96 likely encompass protein coding genes involved in the pathogenesis of COVID-19. 97 The Lung eQTL Consortium cohort used in this gene network analysis is described in Table 100 1. Supplementary Fig. S1 shows the expression levels of ACE2 and TMPRSS2 in the three centres 101 that are part of the Lung eQTL Consortium (see methods); ACE2 had low to moderate expression 102 levels in lung tissue; whereas TMPRSS2 was highly expressed. Based on the study cohort lung 103 expression profile, we determined that ACE2 and TMPRSS2 were contained in distinct modules. The 104 module containing ACE2 (ACE2 module) included 681 unique genes, while the modules containing 105 TMPRSS2 (TMPRSS2 module) encompassed 1,086 unique genes (Supplementary Tables S1 and S2). 106 Only 41 genes were found in both modules. The hub gene for the ACE2 module was TMEM33, and 107 hub gene for the TMPRSS2 module was PDZD2 (see methods for the definition of 'hub gene'). Table S2 ). Next, we identified 368 genes that 176 were moderately or highly correlated with TMPRSS2 gene expression levels (r>0.30), of those 78 were 177 drug targets or were part of key pathways that could be targeted by drug compounds (see methods). 178 The genes are shown in single gene (all with druggability scores Tier 1-3 12), and Pearson correlation coefficient (r) between 185 the gene and TMPRSS2 within the module is shown on the y axis. Colours of bars represent combined 186 biological information: green (group A1) represents genes related to human diseases based Online 187 Mendelian Inheritance in Man (OMIM) and ClinVar databases; orange (group A2) are genes 188 associated with human diseases, which also have phenotypic information on knockdown or knockout 189 mouse models based on Mouse Genome Informatics (MGI) database; purple (group A3) represents 190 genes associated with human diseases and with genetic variants associated to lung function traits 14; 191 pink (group A4) represents genes associated with a human disease, with phenotypic information on 192 knockdown or knockout mouse, and genetic variants associated with lung function. 193 194 We later explored the drug-gene interactions of the genes described in Fig. 2 ; 53 of these genes 195 were found to interact with known drugs. Furthermore, 21 genes with gene-drug interactions ( There is a scarcity of therapeutic treatments specific for this virus and for severe COVID-19 222 pneumonia. ACE2 and TMPRSS2 are key proteins involved in the cellular entry mechanism of SARS-223 Cov-2 to infect the lungs of the human host. Because one of the rate-limiting step in this process is the 224 overall availability of these proteins on surface of lung epithelial cells 15, careful evaluation of ACE2 225 and TMPRSS2 biology may enable identification of possible therapeutic targets against SARS-Cov-2 226 infection. In this study, by using a network analysis of genome-wide gene expression in lung tissue, 227 we were able to identify a set of genes that may interact with ACE2 and TMPRSS2, and thus may be 228 drug targets. HDAC8 inhibition ameliorates PF 31; moreover we found that cigarette exposure, a known risk factor 264 for both COVID-19 and IPF, increases the expression of HDAC8 in lung tissue. Therefore, targeting 265 the PF mechanisms through HDAC inhibitors pose an interesting therapy to further explore. 266 The 'entry into host cell' biological process was enriched with genes from the TMPRSS2 268 module. Furthermore, the CD55 or complement decay-accelerating factor, an inhibitor of complement 269 activation, is one of the few genes that was part of this process. The complement system has a major 270 role in the immune response to viruses and triggers a proinflammatory cascade 32. CD55, which is 271 highly expressed in lung tissue, prevents the formation of C3 convertase 33 and therefore also inhibits 272 the formation of C3 complement. C3-deficient mice show less respiratory dysfunction and lower levels 273 of cytokines and chemokines in lungs in response to SARS-CoV 34. Thus, it is possible that preventing 274 the formation of C3 via CD55 could be beneficial in COVID-19. Fortunately, known compounds such 275 as chloramphenicol already exist that specifically target CD55 32,35. 276 As noted above, we have identified a set of genes that interact with potential therapeutic targets, 278 which could be explored as treatments against COVID-19. The main strength of our study is the large 279 number of lung tissue specimens with detailed clinical phenotypic data. This allowed us to not only 280 identify genes related to ACE2 and TMPRSS2 expression, but also to determine the effects of various 281 clinical factors on the lung tissue expression of these genes. However, there were limitations to this 282 study. First, we used an in-silico approach to identify ACE2 and TMPRSS2 correlated genes, but we 283 did not confirm these association in vivo nor determine how these correlated genes physically 284 interacted with ACE2 and TMPRSS2. Second, we identified the most promising drugs based on drug-285 gene interactions from bioinformatic databases, but we are yet to test their effects on gene and/or 286 protein expression in in vitro experiments. Third, the lungs of our study cohort were not exposed to 287 SARS-CoV-2, therefore it is possible that the gene expression of these key identified genes in lung 288 tissue could be changed upon SARS-CoV-2 infection. Lastly, the cohort used for gene expression was Using the WGCNA 37 R package, we explored gene networks correlated to ACE2 and 314 TMPRSS2 in order to identify potential interactions in the Lung eQTL Consortium cohort. WGCNA 315 clusters co-expressed genes into networks and creates "modules", which are defined as groups of 316 highly interconnected genes. For this analysis we identified signed consensus modules among the three 317 centres in our study cohort. Briefly, WGCNA generated a signed co-expression matrix based on the 318 correlation between genes, which later was transformed into an adjacent matrix by raising the co-319 expression to a soft threshold power (β). For our study we used a β=6 and a minimum module size of 320 100 probe sets. A consensus network was built by identifying the overlap of all input datasets. Tier 2 score indicates gene encoding targets with a known bioactive drug-like small molecule binding 343 partner and ≥50% identity (over ≥75% of the sequence) with an approved drug target; and Tier 3 344 denotes protein coding genes with similarities to drug targets and are members of key druggable gene 345 families. We also interrogated the Drug-Gene Interaction database (DGIdb) 13 of the genes. DGIdb 346 defines drug-gene interaction as a known interaction (i.e.: inhibition, activation) between a known 347 drug compound and a target gene. 348 349 Differential expression of ACE2 and TMPRSS2 correlated genes 350 351 diabetes, asthma, COPD, cardiac disease, and hypertension) on the expression of druggable genes that 353 were correlated with ACE2 or TMPRSS2. We first combined the gene expression from the three centres 354 using ComBat from the R package sva to correct for any batch effect 39. Then, the differential 355 expression was assessed for each gene-risk factor pair by a robust linear regression using the package 356 MASS 40 in R, in which the dependent variable was the gene expression and the explanatory variable 357 was the risk factor. The differential expression analysis on smoking was adjusted for sex and age, and 358 the analyses on diabetes, COPD and cardiac disease and hypertension were additionally adjusted for 359 smoking status. We set statistically significant differential expression FDR<0.05. 360 Aetiology: Koch's postulates fulfilled for SARS virus Epidemiology and cause of severe acute respiratory syndrome (SARS) in People's Republic of China Identification of a novel coronavirus in patients with severe acute respiratory 371 syndrome Clinical features of patients infected with 2019 novel coronavirus in Wuhan Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: 375 implication for development of RBD protein as a viral attachment inhibitor and vaccine SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked 378 by a Clinically Proven Protease Inhibitor The Genome sequence of the SARS-associated coronavirus Characterization of a novel coronavirus associated with severe acute respiratory 382 syndrome Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Respiratory Syndrome Coronavirus and Human Coronavirus NL63 Evidence that TMPRSS2 activates the severe acute respiratory syndrome 389 coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune 390 response The druggable genome and support for target identification and validation in drug 392 development DGIdb 2.0: mining clinically relevant drug-gene interactions New genetic signals for lung function highlight pathways and chronic 396 obstructive pulmonary disease associations across multiple ancestries SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in 399 bronchial transient secretory cells Exploitation for Therapeutic Gain The equilibrative nucleoside transporter family, SLC29. Pflugers Arch Inhibition of adenosine kinase attenuates acute lung injury Identification of Host Kinase Genes Required for Influenza Virus Replication 407 and the Regulatory Role of MicroRNAs Metabolic pathways for the activation of the antiretroviral agent 2',3'-409 dideoxyadenosine in human lymphoid cells Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-411 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area DPP-4 inhibitors and risk of infections: a meta-analysis of 416 randomized controlled trials IL-13 and idiopathic pulmonary fibrosis: Possible links and new 418 therapeutic strategies Chronic obstructive pulmonary disease is associated with 420 the -1055 IL-13 promoter polymorphism Inverse association of plasma IL-13 and inflammatory chemokines with lung 422 function impairment in stable COPD: a cross-sectional cohort study COVID-19: risk for cytokine targeting in chronic 424 inflammatory diseases? Histone deacetylase: a potential therapeutic target for fibrotic disorders Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary 428 fibrosis Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-430 HDAC8 inhibition ameliorates pulmonary fibrosis Complement as a target in COVID-19? Beyond the Role of CD55 as a Complement Component Complement Activation Contributes to Severe Acute Respiratory 438 COVID-19: immunopathology and its implications for therapy Lung eQTLs to help reveal the molecular underpinnings of asthma WGCNA: an R package for weighted correlation network analysis Conducting Meta-Analyses in R with the metafor Package The sva package for 448 removing batch effects and other unwanted variation in high Applied Statistics with S The eQTL data from Laval University were generated from tissues obtained through the Quebec 455 Research Respiratory Network Biobank, IUCPQ site. We acknowledge Compute Canada and 456 provided lung expression data and revised the manuscript The full results obtained in this analysis are provided in the Supplementary Tables associated to this 362 manuscript. 363